
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7860373/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Activation of the GPR35 pathway drives angiogenesis in the tumour microenvironment. Gut, 2022, 71, 509-520.	6.1	41
2	Epithelial X-Box Binding Protein 1 Coordinates Tumor Protein p53-Driven DNA Damage Responses and Suppression of Intestinal Carcinogenesis. Gastroenterology, 2022, 162, 223-237.e11.	0.6	15
3	Two microbiota subtypes identified in irritable bowel syndrome with distinct responses to the low FODMAP diet. Gut, 2022, 71, 1821-1830.	6.1	63
4	PUFA-Induced Metabolic Enteritis as a Fuel for Crohn's Disease. Gastroenterology, 2022, 162, 1690-1704.	0.6	24
5	A purine metabolic checkpoint that prevents autoimmunity and autoinflammation. Cell Metabolism, 2022, 34, 106-124.e10.	7.2	23
6	Interleukin-23 in the Pathogenesis of Inflammatory Bowel Disease and Implications for Therapeutic Intervention. Journal of Crohn's and Colitis, 2022, 16, ii3-ii19.	0.6	36
7	IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus. Clinical Gastroenterology and Hepatology, 2022, 20, 2619-2627.e1.	2.4	9
8	Paneth Cell Alertness to Pathogens Maintained by Vitamin D Receptors. Gastroenterology, 2021, 160, 1269-1283.	0.6	69
9	Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study. Journal of Crohn's and Colitis, 2021, 15, 2001-2010.	0.6	27
10	Is IL-6 Back in trans Signaling for Inflammatory Bowel Disease?. Gastroenterology, 2021, 160, 2247-2249.	0.6	0
11	Prostanoids put a brake on necroptosis in IBD. Nature Cell Biology, 2021, 23, 680-681.	4.6	2
12	SREBP1-induced fatty acid synthesis depletes macrophages antioxidant defences to promote their alternative activation. Nature Metabolism, 2021, 3, 1150-1162.	5.1	29
13	Finding the right target for drug-resistant inflammatory bowel disease. Nature Medicine, 2021, 27, 1870-1871.	15.2	2
14	Interleukin-22 orchestrates a pathological endoplasmic reticulum stress response transcriptional programme in colonic epithelial cells. Gut, 2020, 69, 578-590.	6.1	84
15	Genetic Risk of Severe Covid-19. New England Journal of Medicine, 2020, 383, 1590-1591.	13.9	22
16	Activating Transcription Factor 6 Mediates Inflammatory Signals in Intestinal Epithelial Cells Upon Endoplasmic Reticulum Stress. Gastroenterology, 2020, 159, 1357-1374.e10.	0.6	73
17	GM-CSF Calibrates Macrophage Defense and Wound Healing Programs during Intestinal Infection and Inflammation. Cell Reports, 2020, 32, 107857.	2.9	79
18	Macrophage metabolic reprogramming presents a therapeutic target in lupus nephritis. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 15160-15171.	3.3	90

#	Article	IF	CITATIONS
19	Crohn's disease. Nature Reviews Disease Primers, 2020, 6, 22.	18.1	420
20	FAMIN Is a Multifunctional Purine Enzyme Enabling the Purine Nucleotide Cycle. Cell, 2020, 180, 278-295.e23.	13.5	42
21	Dietary lipids fuel GPX4-restricted enteritis resembling Crohn's disease. Nature Communications, 2020, 11, 1775.	5.8	143
22	IDO1+ Paneth cells promote immune escape of colorectal cancer. Communications Biology, 2020, 3, 252.	2.0	26
23	Impaired Autophagy in CD11b ⁺ Dendritic Cells Expands CD4 ⁺ Regulatory T Cells and Limits Atherosclerosis in Mice. Circulation Research, 2019, 125, 1019-1034.	2.0	31
24	Epithelial endoplasmic reticulum stress orchestrates a protective IgA response. Science, 2019, 363, 993-998.	6.0	51
25	Trial summary and protocol for a phase II randomised placebo-controlled double-blinded trial of Interleukin 1 blockade in Acute Severe Colitis: the IASO trial. BMJ Open, 2019, 9, e023765.	0.8	25
26	Control of CD1d-restricted antigen presentation and inflammation by sphingomyelin. Nature Immunology, 2019, 20, 1644-1655.	7.0	35
27	GPR35 promotes glycolysis, proliferation, and oncogenic signaling by engaging with the sodium potassium pump. Science Signaling, 2019, 12, .	1.6	58
28	ATG16L1 orchestrates interleukin-22 signaling in the intestinal epithelium via cGAS–STING. Journal of Experimental Medicine, 2018, 215, 2868-2886.	4.2	122
29	Personalized Treatment in Inflammatory Bowel Disease: For Another Time. Gastroenterology, 2018, 155, 963-964.	0.6	3
30	Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study. The Lancet Gastroenterology and Hepatology, 2018, 3, 671-680.	3.7	126
31	New Insights Into the Regulation of Natural-Killer Group 2 Member D (NKG2D) and NKG2D-Ligands: Endoplasmic Reticulum Stress and CEA-Related Cell Adhesion Molecule 1. Frontiers in Immunology, 2018, 9, 1324.	2.2	21
32	Long-term Efficacy of Vedolizumab for Crohn's Disease. Journal of Crohn's and Colitis, 2017, 11, jjw176.	0.6	141
33	Long-term Efficacy of Vedolizumab for Ulcerative Colitis. Journal of Crohn's and Colitis, 2017, 11, jjw177.	0.6	140
34	Defective ATG16L1-mediated removal of IRE1α drives Crohn's disease–like ileitis. Journal of Experimental Medicine, 2017, 214, 401-422.	4.2	141
35	Reversal of murine alcoholic steatohepatitis by pepducin-based functional blockade of interleukin-8 receptors. Gut, 2017, 66, 930-938.	6.1	39
36	Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet, The, 2017, 389, 1699-1709.	6.3	364

#	Article	IF	CITATIONS
37	A role for oncostatin M in inflammatory bowel disease. Nature Medicine, 2017, 23, 535-536.	15.2	20
38	CD1d-Restricted pathways in hepatocytes control local natural killer T cell homeostasis and hepatic inflammation. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 10449-10454.	3.3	26
39	The road to Crohn's disease. Science, 2017, 357, 976-977.	6.0	8
40	Intestinal epithelial cell endoplasmic reticulum stress promotes MULT1 up-regulation and NKG2D-mediated inflammation. Journal of Experimental Medicine, 2017, 214, 2985-2997.	4.2	52
41	Epithelial calcineurin controls microbiota-dependent intestinal tumor development. Nature Medicine, 2016, 22, 506-515.	15.2	93
42	Lipocalin 2 Protects from Inflammation and Tumorigenesis Associated with Gut Microbiota Alterations. Cell Host and Microbe, 2016, 19, 455-469.	5.1	244
43	C13orf31 (FAMIN) is a central regulator of immunometabolic function. Nature Immunology, 2016, 17, 1046-1056.	7.0	123
44	Epithelial IL-23R Signaling Licenses Protective IL-22 Responses in Intestinal Inflammation. Cell Reports, 2016, 16, 2208-2218.	2.9	89
45	Novel aspects of autoimmunity. Immunology and Cell Biology, 2016, 94, 917-917.	1.0	0
46	Paternal chronic colitis causes epigenetic inheritance of susceptibility to colitis. Scientific Reports, 2016, 6, 31640.	1.6	15
47	Discovery of Biomarkers of Response in Early Drug Development. Journal of Crohn's and Colitis, 2016, 10, S560-S566.	0.6	4
48	The unfolded protein response in immunity and inflammation. Nature Reviews Immunology, 2016, 16, 469-484.	10.6	581
49	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	4.3	4,701
50	Endoplasmic Reticulum Stress Is Implicated in Intestinal Failure–Associated Liver Disease. Journal of Parenteral and Enteral Nutrition, 2016, 40, 431-436.	1.3	4
51	HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer. Genome Medicine, 2015, 7, 108.	3.6	138
52	Cholangiocytes derived from human induced pluripotent stem cells for disease modeling and drug validation. Nature Biotechnology, 2015, 33, 845-852.	9.4	318
53	Generation of primary human intestinal T cell transcriptomes reveals differential expression at genetic risk loci for immune-mediated disease. Gut, 2015, 64, 250-259.	6.1	30
54	Failure of interleukin 13 blockade in ulcerative colitis. Gut, 2015, 64, 857-858.	6.1	12

#	Article	IF	CITATIONS
55	The biliary epithelium presents antigens to and activates natural killer T cells. Hepatology, 2015, 62, 1249-1259.	3.6	83
56	α4β7integrin: beyond T cell trafficking. Gut, 2014, 63, 1377-1379.	6.1	15
57	Protective mucosal immunity mediated by epithelial CD1d and IL-10. Nature, 2014, 509, 497-502.	13.7	172
58	IBD Genetics: Focus on (Dys) Regulation in Immune Cells and the Epithelium. Gastroenterology, 2014, 146, 896-899.	0.6	10
59	Not all monoclonals are created equal – Lessons from failed drug trials in Crohn's disease. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2014, 28, 437-449.	1.0	37
60	A Spaetzle-like role for nerve growth factor β in vertebrate immunity to <i>Staphylococcus aureus</i> . Science, 2014, 346, 641-646.	6.0	68
61	Type I interferon signalling in the intestinal epithelium affects Paneth cells, microbial ecology and epithelial regeneration. Gut, 2014, 63, 1921-1931.	6.1	84
62	ATG16L1Crohn's disease risk stresses the endoplasmic reticulum of Paneth cells. Gut, 2014, 63, 1038-1039.	6.1	14
63	Stressful genetics in Crohn's disease. Nature, 2014, 506, 441-442.	13.7	7
64	Characterization of animal models for primary sclerosing cholangitis (PSC). Journal of Hepatology, 2014, 60, 1290-1303.	1.8	129
65	Introduction: the unfolded protein response's role in disease pathophysiology. Seminars in Immunopathology, 2013, 35, 255-257.	2.8	6
66	Paneth cells as a site of origin for intestinal inflammation. Nature, 2013, 503, 272-276.	13.7	605
67	The unfolded protein response and gastrointestinal disease. Seminars in Immunopathology, 2013, 35, 307-319.	2.8	74
68	ER stress transcription factor Xbp1 suppresses intestinal tumorigenesis and directs intestinal stem cells. Journal of Experimental Medicine, 2013, 210, 2041-2056.	4.2	120
69	Autophagy, Microbial Sensing, Endoplasmic Reticulum Stress, and Epithelial Function in Inflammatory Bowel Disease. Gastroenterology, 2011, 140, 1738-1747.e2.	0.6	129
70	The unfolded protein response and its role in intestinal homeostasis and inflammation. Experimental Cell Research, 2011, 317, 2772-2779.	1.2	46
71	Genetically determined epithelial dysfunction and its consequences for microflora–host interactions. Cellular and Molecular Life Sciences, 2011, 68, 3643-3649.	2.4	28
72	Lessons from type I interferons in ulcerative colitis. Gut, 2011, 60, 430-431.	6.1	3

ARTHUR KASER

#	Article	IF	CITATIONS
73	Endoplasmic reticulum stress: implications for inflammatory bowel disease pathogenesis. Current Opinion in Gastroenterology, 2010, 26, 318-326.	1.0	93
74	Survive an innate immune response through XBP1. Cell Research, 2010, 20, 506-507.	5.7	15
75	Genes and Environment: How Will Our Concepts on the Pathophysiology of IBD Develop in the Future?. Digestive Diseases, 2010, 28, 395-405.	0.8	65
76	Inflammatory bowel diseases: highlights from the United European Gastroenterology Week 2008. Expert Opinion on Therapeutic Targets, 2009, 13, 259-263.	1.5	3
77	Endoplasmic reticulum stress in the intestinal epithelium and inflammatory bowel disease. Seminars in Immunology, 2009, 21, 156-163.	2.7	110
78	Microsomal triglyceride transfer protein regulates endogenous and exogenous antigen presentation by group 1 CD1 molecules. European Journal of Immunology, 2008, 38, 2351-2359.	1.6	39
79	Paneth cells and inflammation dance together in Crohn's disease. Cell Research, 2008, 18, 1160-1162.	5.7	22
80	XBP1 Links ER Stress to Intestinal Inflammation and Confers Genetic Risk for Human Inflammatory Bowel Disease. Cell, 2008, 134, 743-756.	13.5	1,225
81	Adaptive immunity in inflammatory bowel disease: state of the art. Current Opinion in Gastroenterology, 2008, 24, 455-461.	1.0	12
82	Role of NKT Cells in the Digestive System. III. Role of NKT cells in intestinal immunity. American Journal of Physiology - Renal Physiology, 2007, 293, G1101-G1105.	1.6	34
83	CD1d-Restricted T Cell Pathways at the Epithelial-Lymphocyte-Luminal Interface. Journal of Pediatric Gastroenterology and Nutrition, 2004, 39, S719-S722.	0.9	2
84	Natural Killer T Cells in Mucosal Homeostasis. Annals of the New York Academy of Sciences, 2004, 1029, 154-168.	1.8	12